Fed’s Powell opens door to potential rate cuts at Jackson Hole
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics INC (NYSE:DGX), sold 1,975 shares of common stock on August 15, 2025, at a price of $180. The total value of the transaction amounted to $355,500. The sale comes as Quest Diagnostics, with a market capitalization of $20.4 billion, trades near its 52-week high of $182.38. According to InvestingPro analysis, the company currently appears overvalued relative to its Fair Value.
Following the transaction, Plewman directly owns 17,244 shares of Quest Diagnostics INC. The company maintains strong fundamentals, with an "InvestingPro Financial Health" score rated as GOOD, and has consistently raised its dividend for 14 consecutive years.
The sale was executed under a Rule 10b5-1 sales plan. The transaction was reported in a Form 4 filing with the Securities and Exchange Commission. Analyst price targets range from $166 to $200, with InvestingPro offering comprehensive insider trading analysis and 8 additional key insights about Quest Diagnostics’ financial outlook.
In other recent news, Quest Diagnostics reported impressive financial results for the second quarter of 2025. The company achieved adjusted earnings per share of $2.62, surpassing the analyst forecast of $2.57. Additionally, Quest Diagnostics exceeded revenue expectations by posting $2.76 billion, compared to the anticipated $2.73 billion. In another development, Quest Diagnostics’ subsidiary, Haystack Oncology, announced a research collaboration with Mass General Brigham. This partnership will study the use of liquid biopsy technology to guide post-surgical treatment decisions for certain cancer patients. The research will focus on two clinical trials involving cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma. Researchers aim to evaluate the effectiveness of the Haystack MRD test in detecting minimal residual disease after treatment. These recent developments highlight Quest Diagnostics’ ongoing efforts in both financial performance and medical research advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.